{"analyses":[{"ciLowerLimit":"0.8","ciPctValue":"95","ciUpperLimit":"3.9","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".17","paramType":"Hazard Ratio (HR)","paramValue":"1.74","statisticalComment":"adjusted for risk category","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"description":"Development of recurrent malignancy after enrollment in the study","groups":[{"description":"Patients receive oral mycophenolate mofetil 1000 mg twice daily.","id":"OG000","title":"Mycophenolate Mofetil"},{"description":"Patients receive oral placebo twice daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"within 4 years","title":"Recurrent Malignancy","type":"SECONDARY","unitOfMeasure":"participants"}